Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Postsurgical Pain
Interventions: CA-008 5 mg, Placebo, Bupivacaine Hydrochloride, Hydromorphone, Fentanyl, Acetaminophen, Oxycodone, CA-008 10 mg, CA-008 15 mg; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Alzheimer Disease
Interventions: NS 2330 (Tesofensine); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 80
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more

Conditions: BK Viremia; BKV DNAemia
Interventions: Anti-BK polyomavirus (AntiBKV); Biological
Lead sponsor: Memo Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Opioid Use, Spine Fusion
Interventions: Spinal Fusion Preoperative Opioid Taper, Non-taper Control; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Motion Sickness
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: San Diego, California • San Jose, California • Santa Monica, California + 2 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more

Conditions: Autism Spectrum Disorder
Interventions: Project Personality, Sharing Feelings Intervention; Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: COVID-19
Interventions: Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment; Biological · Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more

Conditions: Post-Acute COVID-19 Syndrome, Cognitive Dysfunction
Interventions: Pascal device, Sham Device; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoxemia, Acute Mountain Sickness (AMS), Inflammation, Immune Response
Interventions: ACETAZOLAMIDE oral capsule, Placebo Arm; Drug · Device
Lead sponsor: University of California, Riverside; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Riverside, California

Conditions: Ankylosing Spondylitis
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Irvine, California • La Mesa, California • San Leandro, California + 22 more

Conditions: Sleep, Insomnia, Insulin Resistance
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 35 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension, Portal
Interventions: GR-MD-02, Placebo; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 46
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 39 more

Conditions: Neuralgia,Postherpetic
Interventions: Gabapentin Extended Release tablets, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more

Conditions: Major Depressive Disorder
Interventions: CYB003, Psychotherapy, Placebo, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey

Conditions: Analgesia, Pain Catastrophizing, Pain
Interventions: Medoc cutaneous probe, Quantitative sensory testing, Computer tasks; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Colitis Ulcerative, Ulcerative Colitis
Interventions: MK-8690, Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,042 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Birmingham, Alabama • Montgomery, Alabama • Mesa, Arizona + 60 more

Conditions: Urolithiasis, Stones, Kidney, Renal Stones, Kidney Stones
Interventions: CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS), DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS), URETEROSCOPY (URS) WITHOUT SUCTION, PERCUTANEOUS NEPHROLITHOTOMY (PCNL); Device · Procedure
Lead sponsor: Calyxo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Miami, Florida • Wichita, Kansas • Cheektowaga, New York + 6 more

Conditions: Systemic Sclerosis, Diffuse Scleroderma
Interventions: Privigen; Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Sepsis, Kidney Injury, Thiamine Deficiency
Interventions: Thiamine Hydrochloride, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts • Manhasset, New York • New York, New York + 1 more

Conditions: Infections, Bacterial
Interventions: Retapamulin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Diego, California • Honolulu, Hawaii • Baltimore, Maryland + 1 more

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Milford, Connecticut • Stamford, Connecticut • Binghamton, New York + 3 more

Search by objective public record fields.

Study in Subjects Undergoing Complete Abdominoplasty

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Promoting Resilience in Teens With ASD

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

Treatment of Insomnia and Glucose Metabolism

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Test Retest Reliability of OA and OH

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study

IVIG Treatment in Systemic Sclerosis

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Thiamine as a Renal Protective Agent in Septic Shock

Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.